{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:29:50Z","timestamp":1761920990247,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2021.103485","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T21:18:05Z","timestamp":1641244685000},"page":"103485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of rituximab in Mexican patients with Multiple Sclerosis\u2013A single-center retrospective study"],"prefix":"10.1016","volume":"58","author":[{"given":"Elisa","family":"Bribiesca-Contreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Garc\u00eda-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"G\u00f3mez-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizeth","family":"Zertuche-Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodr\u00edguez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Marc\u00edn-Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryori","family":"Delgado-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Rivas-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresita","family":"Corona-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"July","key":"10.1016\/j.msard.2021.103485_bib0015","article-title":"Rituximab in Multiple Sclerosis\u2013Are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2021.103485_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in Multiple Sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2021.103485_bib0016","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/1352458520952036","article-title":"De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in Multiple Sclerosis","volume":"27","author":"Disanto","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2021.103485_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2013A review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"18","key":"10.1016\/j.msard.2021.103485_bib0004","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus\u2013Etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"issue":"xxxx","key":"10.1016\/j.msard.2021.103485_bib0011","article-title":"Socioeconomic status and access to Multiple Sclerosis treatment in Mexico","volume":"52","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.103485_bib0009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for Multiple Sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103485_bib0006","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting Multiple Sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2021.103485_bib0007","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive Multiple Sclerosis\u2013Results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103485_bib0008","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of rituximab for relapsing-remitting Multiple Sclerosis\u2013A systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.msard.2021.103485_bib0003","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/CON.0000000000000737","article-title":"Phases and phenotypes of Multiple Sclerosis","volume":"25","author":"Kantarci","year":"2019","journal-title":"Continuum Lifelong Learn. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103485_bib0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for Multiple Sclerosis\u20132010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103485_bib0014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in Multiple Sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103485_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of rituximab in Multiple Sclerosis\u2013An observational study from southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2021.103485_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nic.2016.12.001","article-title":"Multiple Sclerosis\u2013Epidemiologic, clinical, and therapeutic aspects","volume":"27","author":"Vidal-Jordana","year":"2017","journal-title":"Neuroimaging Clin. N. Am."},{"issue":"7","key":"10.1016\/j.msard.2021.103485_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on Multiple Sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:39Z","timestamp":1761901419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821007513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":16,"alternative-id":["S2211034821007513"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103485","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of rituximab in Mexican patients with Multiple Sclerosis\u2013A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103485"}}